The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Les autorités sanitaires américaines ont demandé vendredi à Sarepta Therapeutics de cesser volontairement d'expédier son traitement génique Elevidys, à la suite du décès d'un patient ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy ...

La FDA demande à Sarepta Therapeutics de suspendre les expéditions de la thérapie génique Elevidys Publié le 18/07/2025 à 19:41 MT Newswires - Traduit par Zonebourse - Voir l'original ...

While MSN reports that Sarepta’s stock price began to rise on Monday on the heels of the announcement, 5 the company is still ...

Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA ...

US regulators are investigating the death of an 8-year-old boy in Brazil who received Sarepta Therapeutics Inc.’s Elevidys.

A recent FDA investigation has paused further distribution of Elevidys, following reports of at least three patient deaths.